Work

Figure 6 from SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression

Year: 2025

Type: other

Abstract: SM08502 and olaparib remodel the immune TME. A, ID8-OR tumors from mice treated with control, olaparib, SM08502, or in combination (ola + SM) were used for multispectral IHC. Five tumor regions were selected from each mouse (n = 5). B, Assessment of apoptosis via cleaved caspase 3 (CC3)-positive tumor (WT1+) cells. C, Assessment of proliferation Ki67-positive cells. D, Assessment of DNA damage via γH2Ax. E, CD3+ (T cells) and (F) PD-1+CD3+ (PD-1–expressing T cells). G, Tumor-associated macrophages (F4/80+). H, PD-L1+ expression in F4/80+ cells. Outlier analysis via ROUT (Q = 1%) was conducted on all graphs. Error bars, SEM. Statistical test, one-way ANOVA with Tukey multiple comparison correction.

DOI: 10.1158/2767-9764.30783952

Authors: Bradley R. Corr, Elizabeth R. Woodruff, Tomomi M. Yamamoto, Kimberly R. Jordan, Thomas Danhorn, Carine Bossard, Lily L. Nguyen, Edward B. Chuong, Lars Wick, Alexandra Young, Shinya Kusumoto, Sandra Orsulic, Lisa Barroilhet, Benjamin G. Bitler

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4416979529

Cites:

Cited by:

Related to: